Novartis AG SG&A Expenses 2010-2024 | NVS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Novartis AG annual sg&a expenses for 2023 were $12.517B, a 2.66% increase from 2022.
Novartis AG annual sg&a expenses for 2022 were $12.193B, a 18.09% decline from 2021.
Novartis AG annual sg&a expenses for 2021 were $14.886B, a 4.85% increase from 2020.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Novartis AG annual sg&a expenses for 2023 were $12.517B, a 2.66% increase from 2022.
Novartis AG annual sg&a expenses for 2022 were $12.193B, a 18.09% decline from 2021.
Novartis AG annual sg&a expenses for 2021 were $14.886B, a 4.85% increase from 2020.